The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Feasibility of using the drug-induced apoptosis assay (MiCK assay) in mesothelioma as compared to non-small cell lung cancer (NSCLC).
Dennis A. Wigle
Research Funding - DiaTech Oncology
Allan Hallquist
Employment or Leadership Position - DiaTech Oncology
Stock Ownership - DiaTech Oncology
Other Remuneration - DiaTech Oncology
Cary Presant
Employment or Leadership Position - DiaTech Oncology
Consultant or Advisory Role - DiaTech Oncology
Stock Ownership - DiaTech Oncology
Research Funding - DiaTech Oncology
Other Remuneration - DiaTech Oncology
Julian R. Molina
Research Funding - DiaTech Oncology